natgillin/translations-raw huggingface dataset:
Samtidig administration af tenofovirdisoproxilfumarat og didanosin ved en dosis på 400 mg dagligt er blevet forbundet med et signifikant fald i CD4-celletallet, muligvis på grund af en intracellulær interaktion, som øgede fosforyleret (dvs. aktiv) didanosin.
Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Samtidig administration af tenofovirdisoproxilfumarat og didanosin:
Co-administration of tenofovir disoproxil fumarate and didanosine:
Samtidig administration af tenofovirdisoproxilfumarat og NSAID’er kan øge risikoen for nyresvigt.
Concomitant administration of tenofovir disoproxil fumarate and NSAIDs may increase the risk of renal failure.
Samtidig administration af thiaziddiuretika, herunder hydrochlorthiazid, kan øge risikoen for overfølsomhedsreaktioner over for allopurinol.
Co- administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.
Samtidig administration af ticagrelor og heparin, enoxaparin eller desmopressin påvirkede ikke P- aktiveret partiel tromboplastintid (aPTT), aktiveret koagulationstid eller faktor Xa-analyser.
Co-administration of ticagrelor with heparin, enoxaparin or desmopressin had no effect on activated partial thromboplastin time (aPTT), activated coagulation time (ACT) or factor Xa assays.
Samtidig administration af ticagrelor og potente CYP3A-induktorer kan nedsætte eksponeringen for ticagrelor og dets virkning og derfor frarådes samtidig brug af
Co-administration of ticagrelor with potent CYP3A inducers may decrease exposure and efficacy of ticagrelor, therefore, their concomitant use with ticagrelor is discouraged.
Samtidig administration af ticagrelor og stærke CYP3A4-hæmmere (f.eks. ketoconazol, clarithromycin, nefazodon, ritonavir og atazanavir) er kontraindiceret, da det kan medføre en væsentlig stigning i eksponeringen af ticagrelor (se pkt.
Co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir) is contraindicated, as co-administration may lead to a substantial increase in exposure to ticagrelor (see section 4.5).
Samtidig administration af ticagrelor øgede digoxins Cmax med 75 % og AUC med 28 %.
Concomitant administration of ticagrelor increased the digoxin Cmax by 75% and AUC by 28%.
Samtidig administration af Tivicay med visse lægemidler skal undgås i denne population (f.eks. efavirenz, nevirapin, tipranavir/ritonavir eller rifampicin).
Co-administration of Tivicay with some medicines should be avoided in this population (e.g. efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin).
Samtidig administration af tolvaptan og ketoconazol medførte en 440 % stigning i arealet under tidskurven (AUC) og en 248 % stigning i den maksimale observerede plasmakoncentration (Cmax) for tolvaptan.
Co-administration of tolvaptan and ketoconazole resulted in a 440% increase in area under time-concentration curve (AUC) and 248% increase in maximum observed plasma concentration (Cmax) for tolvaptan.
Samtidig administration af Tovanor Breezhaler og oralt inhaleret indacaterol, som er en adrenerg beta2-agonist, havde ingen indvirkning på farmakokinetikken for de to lægemidler under steady state- forhold for begge aktive stoffer.
Concomitant administration of Tovanor Breezhaler and orally inhaled indacaterol, a beta2-adrenergic agonist, under steady-state conditions of both active substances did not affect the pharmacokinetics of either medicinal product.
Samtidig administration af Triumeq og andre lægemidler, der hæmmer UGT1A1, UGT1A3, UGT1A9, CYP3A4 og/eller Pgp, kan derfor øge plasmakoncentrationen af dolutegravir.
Co-administration of Triumeq and other drugs that inhibit UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or P-gp may therefore increase dolutegravir plasma concentration.
Samtidig administration af Triumeq og dofetilid er kontraindiceret på grund af potentiel livstruende toksicitet forårsaget af en høj koncentration af dofetilid (se pkt.
Triumeq and dofetilide co- administration is contraindicated due to potential life-threatening toxicity caused by high dofetilide concentration (see section 4.3).
Samtidig administration af trivalent Fluenz med levende, svækkede vacciner: mæslinger, fåresyge, rubella, varicella og oralt indgivet poliovirus er blevet undersøgt.
The co-administration of trivalent Fluenz with the live attenuated vaccines: measles, mumps, rubella, varicella, and orally-administered poliovirus has been studied.
Samtidig administration af Tybost med lægemidler, som er moderate til svage induktore af CYP3A kan føre til reducerede plasmakoncentrationer af cobicistat og derved til, at atazanavir og darunavir boostes, hvilket kan forårsage svigtende terapeutisk virkning og mulig udvikling af resistens.
Co-administration of Tybost with medicinal products that are moderate to weak inducers of CYP3A may result in decreased plasma concentration of cobicistat and consequently that of atazanavir or darunavir being boosted, leading to loss of therapeutic effect and possible development of resistance.
Samtidig administration af Tybost med lægemidler, som hæmmer CYP3A kan føre til øgede plasmakoncentrationer af cobicistat.
Co-administration of Tybost with medicinal products that inhibit CYP3A may result in increased plasma concentration of cobicistat.
Samtidig administration af Tybost og carbamazepin er kontraindiceret (se pkt.
Co-administration of Tybost with carbamazepine is contraindicated (see section 4.3).
Samtidig administration af Tybost og lægemidler, som er potente induktorer af CYP3A (såsom prikbladet perikum (Hypericum perforatum), rifampicin, carbamazepin, phenobarbital og phenytoin) kan føre til reducerede plasmakoncentrationer af cobicistat og derved til, at atazanavir eller darunavir boostes, hvilket kan forårsage svigtende terapeutisk virkning og mulig udvikling af resistens (se pkt.
Co-administration of Tybost with medicinal products that are strong inducers of CYP3A (such as St. John’s wort (Hypericum perforatum), rifampicin, carbamazepine, phenobarbital, phenytoin) may result in decreased plasma concentrations of cobicistat and consequently that of atazanavir or darunavir being boosted, leading to loss of therapeutic effect and possible development of resistance (see section 4.3).
Samtidig administration af Tybost og rifabutin anbefales ikke.
Co-administration of Tybost and rifabutin is not recommended.
Samtidig administration af valdecoxib og glibenclamid (CYP3A4-substrat) påvirkede hverken glibenclamids farmakokinetik (eksponering) eller farmakodynamik (blodsukker og insulinniveauer).
Co-administration of valdecoxib with glibenclamide (CYP3A4 substrate) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glibenclamide.
Samtidig administration af valdecoxib og lithium medførte signifikante fald i lithiums serumclearance (25%) og renale clearance (30%) med en 34% højere serumeksponering sammenlignet med lithium alene.
Co-administration of valdecoxib and lithium produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
Samtidig administration af vardenafil og HIV-proteaseinhibitorer som for eksempel ritonavir og indinavir er kontraindiceret, da de er meget potente CYP3A4-inhibitorer (se pkt.
Concomitant use of vardenafil with HIV protease inhibitors such as ritonavir and indinavir is contraindicated, as they are very potent inhibitors of CYP3A4 (see section 4.5).
Samtidig administration af veterinærlægemiddelet med andre antihypertensive stoffer (som f.eks. kalciumkanalblokkere, β-blokkere eller diuretika), anæstetika eller sedativa kan potentielt have en additiv, hypotensiv effekt.
The concomitant administration of the product with other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may potentially lead to additive hypotensive effects.
Samtidig administration af veterinærlægemidlet med andre antihypertensive stoffer (som f.eks. kalciumkanalblokkere, β-blokkere eller diuretika), anæstetika eller sedativa kan potentielt have en additiv, hypotensiv effekt.
The concomitant administration of this veterinary medicinal product with other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may potentially lead to additive hypotensive effects.
Samtidig administration af veterinærlægemidlet med andre kaliumbesparende lægemidler (som angiotensionreceptorblokkere, β-blokkere, kalciumkanalblokkere) kan potentielt føre til hyperkaliæmi. (se afsnit 4.5).
The concomitant administration of this veterinary medicinal product with other potassium-sparing treatments (such as ß-blockers, calcium channels blockers, angiotensin receptor blockers) may potentially lead to hyperkalaemia (see section 4.5).
Samtidig administration af veterinærlægemidlet med andre kaliumbesparende lægemidler (som angiotensionreceptorblokkere, β-blokkere, kalciumkanalblokkere) kan potentielt føre til hyperkaliæmi. (se afsnit ”Særlige forsigtighedsregler vedrørende brug til dyr”).
The concomitant administration of this veterinary medicinal product with other potassium-sparing treatments (such as ß-blockers, calcium channels blockers, angiotensin receptor blockers) may potentially lead to hyperkalaemia (see section "Special precautions for use in animals").
Samtidig administration af Viekirax med dasabuvir og lægemidler, der er moderate eller stærke enzym- inducere, forventes at reducere plasmakoncentrationen af ombitasvir, paritaprevir og dasabuvir og deres terapeutiske virkning.
Co-administration of Viekirax and dasabuvir with medicinal products that are moderate or strong enzyme inducers is expected to decrease ombitasvir, paritaprevir, ritonavir and dasabuvir plasma concentrations and reduce their therapeutic effect.
Samtidig administration af Viekirax og andre antivirale midler er ikke undersøgt og anbefales derfor ikke.
Co- administration of Viekirax with other antivirals has not been studied and therefore cannot be recommended.
Samtidig administration af VIRACEPT og tadalafil til behandling af pulmonal arteriel hypertension anbefales ikke.
Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with Viracept is not recommended.
Samtidig administration af Vitekta med stærke CYP3A-inducere (inklusive prikbladet perikum [Hypericum perforatum], rifampicin, carbamazepin, phenobarbital og phenytoin) er kontraindiceret (se pkt.
Co-administration of Vitekta with strong CYP3A inducers (including St. John’s wort [Hypericum perforatum], rifampicin, carbamazepine, phenobarbital and phenytoin) is contraindicated (see sections 4.3 and 4.5).
Samtidig administration af voriconazol og everolimus anbefales ikke, fordi voriconazol antages at øge koncentrationen af everolimus signifikant.
Co-administration of voriconazole with everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations.
Samtidig administration af voriconazol og everolimus anbefales ikke, fordi voriconazol antages at øge koncentrationen af everolimus signifikant.
Coadministration of voriconazole with everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations.
Samtidig administration af voriconazol og lav-dosis ritonavir (100 mg to gange daglig), som findes i Kaletra, bør undgås, medmindre en vurdering af fordele/ulemper for patienten retfærdiggør anvendelsen af voriconazol.
Co-administration of voriconazole and low dose ritonavir (100 mg BID) as contained in Kaletra should be avoided unless an assessment of the benefit/risk to patient justifies the use of voriconazole.
Samtidig administration af voriconazol og lav-dosis ritonavir (100 mg to gange daglig), som findes i Kaletra, bør undgås, medmindre en vurdering af fordele/ulemper for patienten retfærdiggør anvendelsen af voriconazol.
voriconazole and low dose ritonavir (100 mg BID) as contained in Kaletra should be avoided unless an assessment of the benefit/risk to patient justifies the use of voriconazole.
Samtidig administration af voriconazol og lav-dosis ritonavir (100 mg to gange daglig), som findes i lopinavir/ritonavir, bør undgås, medmindre en vurdering af fordele/ulemper for patienten retfærdiggør anvendelsen af voriconazol.
Co-administration of voriconazole and low dose ritonavir (100 mg BID) as contained in lopinavir/ritonavir tablets should be avoided unless an assessment of the benefit/risk to patient justifies the use of voriconazole.
Samtidig administration af voriconazol og lavdosis ritonavir (100 mg 2 gange dagligt) bør undgås, medmindre en vurdering af benefit/risk forholdet for patienten retfærdiggør brugen af voriconazol (se pkt.
Co-administration of voriconazole and low dose ritonavir (100 mg twice daily) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole (see sections 4.5 and 4.3).
Samtidig administration af voriconazol og rifabutin skal undgås, medmindre fordelen ved behandling udvejer risikoen.
Concomitant use of voriconazole and rifabutin should be avoided unless the benefit outweighs the risk.
Samtidig administration af voriconazol og sirolimus er kontraindiceret (se pkt.
Coadministration of voriconazole and sirolimus is contraindicated (see section 4.3).
Samtidig administration af warfarin (CYP2C9-substrat)
Co-administration with warfarin (a CYP2C9 substrate)
Samtidig administration af warfarin (et CYP2C9-substrat)
Co-administration with warfarin (a CYP2C9 substrate)
Samtidig administration anbefales
Co-administration is not recommended.
Samtidig administration anbefales ikke, da det resulterer i en stigning på 40-60% i den systemiske eksponering for didanosin, hvilket kan øge risikoen for didanosinrelaterede bivirkninger (se pkt.
Co-administration is not recommended because it results in a 40 – 60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Samtidig administration er
Co-administration is contraindicated.
Samtidig administration er kontraindiceret.
Effects on medicinal product levels.
Samtidig administration frarådes derfor.
Therefore, such co- administration is not recommended.
Samtidig administration kan resultere i kompetitiv hæmning af metabolismen af disse lægemidler og skabe grundlag for alvorlige og/eller livstruende bivirkninger såsom hjertearytmier (f.eks. amiodaron, bepridil, quinidin, terfenadin, astemizol, cisaprid, pimozid), respiratorisk depression og/eller forlænget sedation (f.eks. oral triazolam og oral midazolam (se afsnit 4.5 mht parenteral midazolam)), perifere vasospasmer eller iskæmi og iskæmi i andre væv, herunder iskæmi i hjernen henholdsvis hjertet (f.eks. ergotaminderivater).
Co-administration may result in competitive inhibition of the metabolism of these medicinal products and create the potential for serious and/or life-threatening adverse events such as cardiac arrhythmia (e.g. amiodarone, bepridil, quinidine, terfenadine, astemizole, cisapride, pimozide), respiratory depression and /or prolonged sedation (e.g. oral triazolam and oral midazolam (for caution on parenterally administred midazolam, see section 4.5)) or peripheral vasospasm or ischaemia and ischaemia of other tissues, including cerebral or myocardial ischaemia (e.g. ergot derivatives).
Samtidig administration kan sandsynligvis forårsage signifikant reduktion i plasmakoncentrationen af rilpivirin (induktion af CYP3A- enzymer).
Co-administration is likely to cause significant decreases in rilpivirine plasma concentrations (induction of CYP3A enzymes).
samtidig administration med
co-administration with other doses
samtidig administration med
monitored when co-administering
Samtidig administration med Agenerase kan føre til en betydelig stigning i plasmakoncentrationen af PDE5 hæmmerne og antallet af associerede bivirkninger, herunder hypotension, synsforstyrrelser og priapismus (se afsnit 4.4).
Co- administration with Agenerase may substantially increase PDE5 inhibitor plasma concentrations and associated adverse events, including hypotension, visual changes and priapism (see section 4.4).
Samtidig administration med andre hiv-proteasehæmmere (PIs)
Co-administration with other HIV protease inhibitors (PIs)
Samtidig administration med andre veterinærlægemidler bør derfor undgås.
Therefore co-administration of this product with other veterinary medicinal products should be avoided.
Samtidig administration med cobicistat kan føre til øgede plasmakoncentrationer af sildenafil, tadalafil og vardenafil, hvilket kan føre til bivirkninger associeret med PDE-5-hæmmeren.
Co-administration with cobicistat may result in increased sildenafil, tadalafil and vardenafil plasma concentrations, which may result in PDE-5 inhibitor-associated adverse reactions.
Samtidig administration med de følgende lægemidler på grund af risikoen for alvorlige eller livstruende bivirkninger eller svigtende virologisk respons og mulig resistens over for Genvoya (se pkt.
Co-administration with the following medicinal products due to the potential for serious or life-threatening adverse reactions or loss of virologic response and possible resistance to Genvoya (see section 4.5):
Samtidig administration med de følgende lægemidler på grund af risikoen for alvorlige og/eller livstruende hændelser eller svigtende virologisk respons og mulig resistens over for Stribild (se pkt.
Co-administration with the following medicinal products due to the potential for serious and/or life-threatening events or loss of virologic response and possible resistance to Stribild (see section 4.5):
Samtidig administration med dofetilid (se pkt.
Co-administration with dofetilide (see section 4.5).
Samtidig administration med en selektiv MAO-A-hæmmer plus en selektiv MAO-B-hæmmer (se pkt.
Coadministration with a selective MAO-A inhibitor and a selective MAO-B inhibitor (see section 4.5).
Samtidig administration med hypertont saltvand var ikke tilladt i disse undersøgelser.
Concomitant administration with hypertonic saline was not permitted in these trials.
Samtidig administration med hæmmere og induktorer af CYP3A4 og/eller Multidrug efflux pump
Co-administration with inhibitors and inducers of CYP3A4 and/or the multidrug efflux pump
Samtidig administration med lægemidler, der øger koncentrationen af serum-natrium
Co-administration with medicinal products that increase serum sodium concentration
samtidig administration med nevirapin.
daily when co-administered with
Samtidig administration med stoffer, der inducerer CYP3A4-aktivitet, kan reducere effekten af Effentora.
Coadministration with agents that induce 3A4 activity may reduce the efficacy of Effentora.
Samtidig administration med Stribild anbefales ikke.
Co-administration with Stribild is not recommended.
Samtidig administration med Tybost anbefales ikke.
Co-administration with Tybost is not recommended.
samtidig administration med Viekirax med eller uden dasabuvir.
administered with Viekirax with or without dasabuvir.
Samtidig administration med warfarin (et CYP2C9-substrat)
Co-administration with warfarin (a CYP2C9 substrate)
Samtidig administration of kraftige CYP3A4-hæmmere
Co-administration with strong inhibitors of CYP3A4
Samtidig administration til rotter af tipranavir og vitamin E i formen TPGS (d- alphatocopherolpolyethylenglycol 1000 succinat) med en mængde på minimum 2,322 IE/m2 resulterede i en signifikant øget påvirkning af koagulationsparametre, blødningsepisoder og død.
The co-administration of tipranavir with vitamin E in the form of TPGS (d-alphatocopherol polyethylene glycol 1000 succinate) from 2,322 IU/m² upwards in rats resulted in a significant increase in effects on coagulation parameters, bleeding events and death.
Samtidig administration var ikke hyppigere forbundet med lokale eller systemiske reaktioner sammenlignet med administration af AFLUNOV alene.
Co-administration was not associated with higher rates of local or systemic reactions compared to administration of AFLUNOV alone.
Samtidig administrationaf potentielt nefrotoksiske lægemidler bør undgås.
Concurrent administration of potential nephrotoxic drugs should be avoided.
Samtidig alvorlig eller ukontrolleret infektion
Concurrent serious or uncontrolled infection
Samtidig anvendelse af
Concomitant administration of
Samtidig anvendelse af
Concomitant use of
Samtidig anvendelse af
Concomitant use of sildenafil
Samtidig anvendelse af
Concomitant use of voriconazole
Samtidig anvendelse af
Sedative/hypnotics are
Samtidig anvendelse af
The concomitant use of
Samtidig anvendelse af 300 mg-tabletten og et morgenmåltid med højt fedtindhold reducerede maravirocs Cmax og AUC med 33 % hos raske frivillige forsøgspersoner.
Co-administration of a 300 mg tablet with a high fat breakfast reduced maraviroc Cmax and AUC by 33% in healthy volunteers.
Samtidig anvendelse af amiodaron blev begrænset ved den kliniske udvikling af sofosbuvir plus DAA’er.
The concomitant use of amiodarone was limited through the clinical development of sofosbuvir plus DAAs.
Samtidig anvendelse af amiodaron var begrænset under den kliniske udvikling af sofosbuvir plus DAA’er.
The concomitant use of amiodarone was limited through the clinical development of sofosbuvir plus DAAs.
Samtidig anvendelse af andre immunsuppressiva
Concomitant use with other immunosuppressive agents
Samtidig anvendelse af andre midler mod erektil dysfunktion
Concomitant use of other treatments for erectile dysfunction
Samtidig anvendelse af andre systemiske α-adrenerge receptoragonister kan forstærke de uønskede virkninger af denne lægemiddelgruppe hos patienter:
The concomitant use of other systemic alpha adrenergic receptor agonists may potentiate the undesirable effects of this class of medicinal products in patients:
Samtidig anvendelse af andre trombocytfunktionshæmmende midler
Coadministration with other antiplatelet medicinal products
Samtidig anvendelse af axitinib og potente CYP3A4/5-hæmmere kan øge plasmakoncentrationen af axitinib (se pkt.
Co-administration of axitinib with strong CYP3A4/5 inhibitors may increase axitinib plasma concentrations (see section 4.5).
Samtidig anvendelse af axitinib og potente CYP3A4/5-induktorer kan nedsætte plasmakoncen- trationen af axitinib (se pkt.
Co-administration of axitinib with strong CYP3A4/5 inducers may decrease axitinib plasma concentrations (see section 4.5).
Samtidig anvendelse af benzodiazepiner og andre lægemidler
Concomitant use of benzodiazepines and other medicinal products
Samtidig anvendelse af bortezomib og potente CYP3A4-induktorer (f.eks. rifampicin, carbamazepin, phenytoin, phenobarbital og perikon) frarådes derfor, da effekten derved kan blive nedsat.
Therefore, the concomitant use of bortezomib with strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital and St. John’s Wort) is not recommended, as efficacy may be reduced.
Samtidig anvendelse af bosentan (en moderat induktor af CYP3A4, CYP2C9 og muligvis af CYP2C19) 125 mg 2 gange dagligt og oralt administreret sildenafil 80 mg 3 gange dagligt (ved steady-state) i 6 dage gav et fald i sildenafils AUC på 63% hos raske frivillige forsøgspersoner.
Co-administration of bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) 125 mg twice daily with oral sildenafil 80 mg three times a day (at steady state) concomitantly administered during 6 days in healthy volunteers resulted in a 63 % decrease of sildenafil AUC.
Samtidig anvendelse af bosentan (en moderat induktor af CYP3A4, CYP2C9 og muligvis af CYP2C19) 125 mg 2 gange dagligt og sildenafil 80 mg 3 gange dagligt (ved steady-state) i 6 dage gav et fald i sildenafils AUC på 63% hos raske frivillige forsøgspersoner.
Co-administration of bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) 125 mg twice daily with sildenafil 80 mg three times a day (at steady state) concomitantly administered during 6 days in healthy volunteers resulted in a 63 % decrease of sildenafil AUC.
Samtidig anvendelse af CYP3A4-inhibitorer
Concomitant use of CYP 3A4 inhibitors